Family · metabolic
Efpeglenatide
LAPS-Exendin-4, HM11260C
A long-acting, exendin-4-based GLP-1 receptor agonist conjugated to an IgG4 Fc fragment, designed for once-weekly subcutaneous dosing. Studied for glucose-dependent insulin secretion, appetite/glycaemic regulation, and cardiovascular/renal risk.
Human clinical data exist: the AMPLITUDE-O trial (n=4076, type 2 diabetes) reported fewer major cardiovascular events and better renal outcomes versus placebo. Despite positive results, the drug is not widely marketed and not approved in most jurisdictions.
- Type 2 diabetes glycaemic-control research
- Cardiovascular-outcomes research (AMPLITUDE-O)
- Renal-outcomes research in high-risk diabetes
Educational overview only — no dosing instructions in the public hub.
As a GLP-1 agonist class effect, gastrointestinal effects (nausea, vomiting, diarrhoea) are the most common in trials. Long-term real-world safety is limited by its restricted approval status; sourcing/purity is an additional practical risk.
Third-party CoA (purity + quantification + MS) is the minimum verification.
Not approved for general marketing in most jurisdictions (including the US and EU) as of 2026; investigational/research status in most markets.
Frequently asked questions
- What is Efpeglenatide used for?
- Type 2 diabetes glycaemic-control research. Cardiovascular-outcomes research (AMPLITUDE-O). Renal-outcomes research in high-risk diabetes. Human clinical data exist: the AMPLITUDE-O trial (n=4076, type 2 diabetes) reported fewer major cardiovascular events and better renal outcomes versus placebo. Despite positive results, the drug is not widely marketed and not approved in most jurisdictions.
- Is Efpeglenatide legal in Europe?
- Not approved for general marketing in most jurisdictions (including the US and EU) as of 2026; investigational/research status in most markets.
- What are the risks and side effects of Efpeglenatide?
- As a GLP-1 agonist class effect, gastrointestinal effects (nausea, vomiting, diarrhoea) are the most common in trials. Long-term real-world safety is limited by its restricted approval status; sourcing/purity is an additional practical risk.
- How is the quality of Efpeglenatide assessed?
- Third-party CoA (purity + quantification + MS) is the minimum verification.